Kyowa Kirin Co (4151) AI Stock Analysis

• Market Cap: ¥1.31T
• Dividend Yield: 2.34%
• Average Volume (3M): 1.28M
• Price to Earnings (P/E): 25.6
• Beta (1Y): 0.40
• Revenue Growth: 8.90%
• EPS Growth: -37.00%
• Country: JP
• Employees: 5,669
• Sector: Healthcare
• Sector Strength: 53
• Industry: Drug Manufacturers - General
• EPS (TTM): 11.78
• Shares Outstanding: 525,634,500
• 10 Day Avg. Volume: 1,084,470
• 30 Day Avg. Volume: 1,278,636
• PEG Ratio: 13.12
• Price to Book (P/B): 2.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 81.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥3,007.11
• Price Target Upside: 21.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: ¥2,773.00 ▲(11.81%Upside)

Kyowa Kirin Co's strong financial performance is the primary driver of its overall score, supported by robust revenue growth and a solid balance sheet. Technical analysis suggests positive momentum, although the stock may be overbought in the short term. Valuation metrics indicate potential overvaluation, tempered by a respectable dividend yield.

Kyowa Kirin Co Business Overview & Revenue Model

Company Description

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

How the Company Makes Money

Kyowa Kirin Co. generates revenue through the sale of its pharmaceutical products, which are developed internally or through partnerships. The company's key revenue streams include the commercialization of its proprietary drugs in global markets, earning income from product sales and licensing agreements. Additionally, Kyowa Kirin collaborates with other pharmaceutical companies and research institutions, engaging in joint ventures and co-development agreements that contribute to its earnings. The company also invests in ongoing research and development to expand its pipeline of drug candidates, ensuring a steady flow of innovative products to maintain and grow its market presence.

Kyowa Kirin Co Financial Statement Overview

Summary

Kyowa Kirin Co demonstrates strong financial health, with substantial revenue growth and solid profitability metrics. The company's balance sheet is robust, with low debt levels and high equity, indicating financial stability. However, there is room for improvement in operating cash flow generation.

Income Statement

Kyowa Kirin Co has shown consistent revenue growth with a strong increase from ¥352.2 billion in 2021 to ¥494.7 billion TTM (Trailing-Twelve-Months). The gross profit margin remains robust, indicating effective cost management. However, there is a slight decrease in net income in the TTM period, affecting the net profit margin.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, demonstrating financial stability. The debt-to-equity ratio is low, indicating prudent leverage management, which is a positive sign for long-term sustainability.

Cash Flow

Operating cash flow has decreased in the TTM period, which could indicate challenges in cash generation. However, the company maintains positive free cash flow, showing efficient capital expenditure management. The free cash flow growth rate has declined, suggesting a need for improved cash flow operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
494.71B	495.56B	442.23B	398.37B	352.25B	318.35B
	Gross Profit
360.11B	362.95B	331.03B	311.46B	264.40B	237.91B
	EBIT
84.91B	91.87B	95.84B	64.81B	61.17B	52.56B
	EBITDA
105.18B	116.65B	118.53B	82.81B	79.86B	74.71B
	Net Income Common Stockholders
51.40B	59.87B	81.19B	53.57B	52.35B	47.03B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
214.37B	244.68B	405.01B	339.72B	336.52B	287.65B
	Total Assets
1.02T	1.07T	1.03T	939.88B	921.87B	801.29B
	Total Debt
22.49B	21.68B	0.00	23.28B	22.54B	18.28B
	Net Debt
-191.88B	-223.01B	-403.08B	-315.92B	-312.55B	-268.74B
	Total Liabilities
187.86B	216.55B	189.52B	177.06B	184.71B	102.89B
	Stockholders Equity
831.42B	850.81B	836.42B	762.83B	737.16B	698.40B
Cash Flow		Free Cash Flow
4.49B	41.85B	82.70B	20.01B	66.78B	4.27B
	Operating Cash Flow
56.09B	67.88B	115.55B	48.67B	86.55B	39.50B
	Investing Cash Flow
-105.92B	-142.39B	-20.38B	-17.18B	-11.36B	252.56B
	Financing Cash Flow
-59.88B	-84.70B	-32.53B	-29.03B	-28.45B	-26.00B

Kyowa Kirin Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2480.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4151, the sentiment is Positive. The current price of 2480 is above the 20-day moving average (MA) of 2369.12, above the 50-day MA of 2252.04, and above the 200-day MA of 2428.68, indicating a bullish trend. The MACD of 75.11 indicates Negative momentum. The RSI at 68.93 is Neutral, neither overbought nor oversold. The STOCH value of 86.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4151.

Kyowa Kirin Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4151	75 Outperform	¥1.31T	25.64	6.04%	2.34%	8.90%	-37.00%
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
ALPMF		$17.18B	51.64	3.22%	5.14%	―	―
CHGCF		$84.50B	31.80	22.80%	1.39%	―	―
DSKYF		$44.87B	24.54	17.60%	1.59%	―	―
ESALF		$7.82B	27.29	5.34%	3.73%	―	―
SGIOF		$15.19B	11.57	12.99%	2.90%	―	―